This is the authors' abstract. We don't add key points for this paper.
Immune thrombocytopenia (ITP) is an acquired autoimmune disease characterized by an isolated platelet count of less than 100,000/μL caused by destruction and reduced production of platelets. Systemic steroid therapy is a mainstay of first-line treatment; however, additional treatment lines are usually necessary due to the very high recurrence rate after therapy completion and steroid resistance. Standard treatment options for steroid resistance or steroid dependence include splenectomy, rituximab or thrombopoietin receptor agonists. The article presents current data on the diagnosics and therapy of ITP, considering the limited access to some forms of treatment in Poland.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Małecki et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: